Precision versus personalised medicine - PMLiVE

2 years ago 36

By Mark Smith, Senior Medical Manager and Hamed Khan, Associate Medical Manager

In caller years, we person witnessed the emergence of therapies with much precise pharmacological targets. Taking an illustration from oncology, accepted chemotherapy relies connected the rule of cytotoxicity. By prevention of compartment proliferation done inhibition of assorted phases of the compartment cycle, non-targeted termination of cells was the archetypal pharmacological method of treating cancer. Whilst assorted agents from this epoch of anticancer therapy were effective, this was a non-specific, ‘shotgun’ approach, resulting successful the decease of non-cancerous cells arsenic well. For this reason, chemotherapy is well-known for its propensity to origin galore adverse events, including alopecia, nausea, and humor dyscrasias.1 To date, healthcare professionals indispensable tread cautiously erstwhile balancing illness power with unacceptable (and perchance fatal) toxicities associated with cytotoxic chemotherapy.

The emergence of drugs with higher selectivity oregon specificity to pharmacological targets has altered the scenery of crab therapy, and modern medicine arsenic a whole. ‘Targeted therapy’ is simply a wide word that often refers to the usage of drugs that people circumstantial proteins, compartment aboveground molecules, oregon genes.2 The conception of targeted therapy allows for improved efficacy and less adverse events owed to higher selectivity and/or specificity. Newer molecules person advantages arsenic targeted therapy successful that their size allows them to walk easy done compartment membranes to scope intended intracellular targets. Some are designed truthful that highly circumstantial antigenic targeting allows for precise immune-mediated compartment destruction.3,4,5

Another word – ‘precision medicine’ – is often utilized to notation to medicines tailored to the idiosyncratic successful accordance with their genes, situation and lifestyle.6 This tin use astatine a diagnostic and predictive level, for illustration erstwhile selecting for crab screening oregon cardiac hazard assessments based connected household history. Precision medicine tin besides use astatine a therapeutic level, arsenic seen successful assorted cancers wherever biomarkers are identified to observe the beingness of definite tumour cells and place targets for anticancer therapy.

‘Personalised medicine,’ is sometimes utilized interchangeably with ‘precision medicine’. However, whilst galore modern agents are so precise, with precocious selectivity and specificity for pharmacological targets, the question remains whether these approaches are genuinely personalised. The connection ‘personalised’ implies that attraction is uniquely tailored to beryllium circumstantial to the patient, which is untrue for astir targeted therapies. Interestingly, it is present imaginable to cod a patient’s immune cells, reprogram them to people antigens associated with cancerous cells, and past reintroduce them to the patient. These modified immune cells are past capable to recognise the tumour cells and nonstop an immune effect whereby facilitating their elimination.7,8 This is arguably an illustration of personalised therapy, successful that the genetically engineered cells are unsocial to each patient. This exertion could beryllium extended retired of the oncological setting9, though the benefit-risk ratio would request to beryllium considered, arsenic specified therapies are costly, time-consuming, and associated with perchance life-threatening broadside effects.8

Great strides person besides been made successful diagnostics via molecular testing, with whole-genome sequencing and next-generation sequencing becoming much readily available.10 These newer technologies person greater sensitivity compared with accepted azygous cistron sequencing techniques.

Whilst whole-genome sequencing offers sizeable diagnostic benefits for patients, determination stay sizeable barriers to its wide implementation successful objective practice, including deficiency of reimbursement, constricted accessibility, and inadequate standardisation of processes.11 As these components improve, a personalised attack to a greater fig of diseases volition go much accessible. This mightiness adjacent widen to encompass a much holistic attack to healthcare. For example, we mightiness beryllium capable to pre-empt if a diligent is genetically much susceptible to definite broadside effects and tailor management, arsenic necessary.

Precision therapy whitethorn already beryllium here, but truthful excessively are the foundations of genuinely personalised medicine.

References

  1. NICE. BNF. Cytotoxic Drugs. Available at: https://bnf.nice.org.uk/treatment-summaries/cytotoxic-drugs. Accessed November 2022
  2. Cancer.net. What is targeted therapy? Available at: https://www.cancer.net/navigating-cancer-care/how-cancer-treated/personalized-and-targeted-therapies/what-targeted-therapy. Accessed November 2022
  3. UptoDate. Overview of therapeutic monoclonal antibodies. Available at: https://www.uptodate.com/contents/overview-of-therapeutic-monoclonal-antibodies?search=monoclonal%20antibodies&source=search_result&selectedTitle=1~150&usage_type=default&display_rank=1#H2824611726. Accessed November 2022
  4. Cancer Research UK. Monoclonal antibodies. Available at: https://www.cancerresearchuk.org/about-cancer/cancer-in-general/treatment/immunotherapy/types/monoclonal-antibodies. Accessed November 2022
  5. AstraZeneca. Small Molecules. Available at: https://www.astrazeneca.com/r-d/next-generation-therapeutics/small-molecule.html. Accessed November 2022
  6. US FDA. Precision Medicine. Available at: https://www.fda.gov/medical-devices/in-vitro-diagnostics/precision-medicine. Accessed November 2022
  7. Marshall CR, et al. Genome Med. 2020;27:48.
  8. ESMO Daily Reporter. CAR-T-cell therapy. Available at: https://dailyreporter.esmo.org/esmo-congress-2021/opinions/car-t-cell-therapy-the-ultimate-personalised-treatment. Accessed November 2022
  9. Qin VM, et al. Cancers (Basel). 2021;13:404
  10. Petersen BS, et al. BMC Genet. 2017;18:14
  11. Panell M, et al. JCO Precis Oncol. 2019;3:1–9
Read Entire Article